Tenvie Therapeutics has initiated a Phase 1 clinical trial for TNV108, an allosteric inhibitor targeting SARM1, aimed at treating peripheral neuropathies. This marks the second candidate from Tenvie’s product engine to enter clinical development, with the first subject dosed in the trial designed to assess safety and tolerability in healthy volunteers. Preliminary data, including safety and pharmacokinetic profiles, is anticipated in the latter half of 2026.

The significance of TNV108 lies in its potential to be the first disease-modifying therapy for peripheral neuropathies, particularly diabetic peripheral neuropathy (DPN). Current treatments primarily manage neuropathic pain without addressing the underlying axonal degeneration responsible for the condition. By targeting SARM1, a critical mediator of axonal degeneration that disrupts NAD+ metabolism, TNV108 aims to prevent irreversible nerve damage and improve patient outcomes. Preclinical studies have shown promising results, demonstrating robust protection against nerve degeneration in models of both diet- and chemotherapy-induced peripheral neuropathy.

The development of TNV108 could shift the paradigm in peripheral neuropathy treatment by providing a mechanism-based approach that not only alleviates symptoms but also modifies disease progression. This could accelerate the timeline for drug development in this area, as it establishes a framework for future therapies targeting similar pathways in neurological disorders. The focus on structural and blood-based biomarkers of axonal integrity in the trial further underscores the potential for TNV108 to inform clinical practice and enhance our understanding of peripheral nerve health.

Source: globenewswire.com